178 related articles for article (PubMed ID: 29285591)
1. Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.
Capellades J; Puig J; Domenech S; Pujol T; Oleaga L; Camins A; Majós C; Diaz R; de Quintana C; Teixidor P; Conesa G; Plans G; Gonzalez J; García-Balañà N; Velarde JM; Balaña C
J Neurooncol; 2018 Apr; 137(2):367-377. PubMed ID: 29285591
[TBL] [Abstract][Full Text] [Related]
2. Impact of removed tumor volume and location on patient outcome in glioblastoma.
Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
[TBL] [Abstract][Full Text] [Related]
3. Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era.
Kim YJ; Lee DJ; Park CK; Kim IA
Neurosurg Rev; 2019 Dec; 42(4):937-950. PubMed ID: 30612289
[TBL] [Abstract][Full Text] [Related]
4. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection.
Shinoda J; Sakai N; Murase S; Yano H; Matsuhisa T; Funakoshi T
J Neurooncol; 2001 Apr; 52(2):161-71. PubMed ID: 11508816
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression in glioblastoma patients: the impact of extent of resection.
Park HH; Roh TH; Kang SG; Kim EH; Hong CK; Kim SH; Ahn SS; Lee SK; Choi HJ; Cho J; Kim SH; Lee KS; Suh CO; Chang JH
J Neurooncol; 2016 Feb; 126(3):559-66. PubMed ID: 26608521
[TBL] [Abstract][Full Text] [Related]
6. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Bloch O; Han SJ; Cha S; Sun MZ; Aghi MK; McDermott MW; Berger MS; Parsa AT
J Neurosurg; 2012 Dec; 117(6):1032-8. PubMed ID: 23039151
[TBL] [Abstract][Full Text] [Related]
7. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.
Pessina F; Navarria P; Cozzi L; Ascolese AM; Simonelli M; Santoro A; Clerici E; Rossi M; Scorsetti M; Bello L
J Neurooncol; 2017 Oct; 135(1):129-139. PubMed ID: 28689368
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Survival Outcomes Between Partial Resection and Biopsy for Primary Glioblastoma: A Propensity Score-Matched Study.
Byun J; Kim YH; Nam SJ; Park JE; Cho YH; Kim HS; Hong SH; Kim JH; Kim SJ; Kim CJ
World Neurosurg; 2019 Jan; 121():e858-e866. PubMed ID: 30315970
[TBL] [Abstract][Full Text] [Related]
9. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
10. Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines.
Capellades J; Teixidor P; Villalba G; Hostalot C; Plans G; Armengol R; Medrano S; Estival A; Luque R; Gonzalez S; Gil-Gil M; Villa S; Sepulveda J; García-Mosquera JJ; Balana C
Clin Transl Oncol; 2017 Jun; 19(6):727-734. PubMed ID: 28005261
[TBL] [Abstract][Full Text] [Related]
11. Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival.
Coburger J; Hagel V; Wirtz CR; König R
PLoS One; 2015; 10(6):e0131872. PubMed ID: 26115409
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
13. Positive influence of partial resection on overall survival of patients with overlapping glioblastomas.
Quick-Weller J; Tritt S; Baumgarten P; Konczalla J; Kashefiolasl S; Noack A; Tichy J; Seifert V; Marquardt G
Clin Neurol Neurosurg; 2017 Oct; 161():22-28. PubMed ID: 28837843
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database.
Trifiletti DM; Alonso C; Grover S; Fadul CE; Sheehan JP; Showalter TN
World Neurosurg; 2017 Jul; 103():330-340. PubMed ID: 28427986
[TBL] [Abstract][Full Text] [Related]
16. Effects of 5-ALA dose on resection of glioblastoma.
Michael AP; Watson VL; Ryan D; Delfino KR; Bekker SV; Cozzens JW
J Neurooncol; 2019 Feb; 141(3):523-531. PubMed ID: 30644009
[TBL] [Abstract][Full Text] [Related]
17. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
[TBL] [Abstract][Full Text] [Related]
19. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
20. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
